Oncocyte (NASDAQ:IMDX) Cut to Sell at Wall Street Zen

Wall Street Zen cut shares of Oncocyte (NASDAQ:IMDX – Free Report) from a hold rating to a sell rating in a research note released on Saturday.

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Oncocyte in a research note on Wednesday, June 24th. One analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Oncocyte presently has a consensus rating of “Hold” and an average price target of $12.00.

Get Oncocyte alerts:

Get Our Latest Stock Analysis on IMDX

Oncocyte Stock Down 1.2%

Shares of NASDAQ:IMDX opened at $4.27 on Friday. Oncocyte has a 52-week low of $2.33 and a 52-week high of $8.51. The company has a 50 day moving average of $5.05 and a two-hundred day moving average of $5.05. The company has a market capitalization of $139.71 million, a price-to-earnings ratio of -2.87 and a beta of 1.79.

Oncocyte (NASDAQ:IMDX – Get Free Report) last posted its quarterly earnings data on Monday, August 10th. The company reported ($0.23) earnings per share (EPS) for the quarter. The firm had revenue of $0.24 million for the quarter.

Oncocyte Company Profile

(Get Free Report)

Oncocyte (NASDAQ:IMDX) is a molecular diagnostics company that develops and commercializes tests intended to improve cancer detection, risk stratification and treatment decision-making. The company focuses on creating assays that provide clinically actionable information to physicians managing patients with suspected or confirmed malignancies, with particular emphasis on tools that can help evaluate lung nodules and other oncology-related diagnostic challenges.

Oncocyte’s product and development efforts center on blood- and tissue-based molecular assays that analyze biomarkers and genomic signals to inform clinical workflows.

Read More

• Five stocks we like better than Oncocyte
• Commodities Are Booming, But These 3 ETFs Tell Different Stories
• 3 Active ETFs Making Big Moves in August
• This ETF Is Outperforming by Avoiding the S&P 500’s Biggest Problem
• Birkenstock Beats the Skeptics—But Not on EPS

Receive News & Ratings for Oncocyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oncocyte and related companies with MarketBeat.com's FREE daily email newsletter.